Michael J. Purcell, Director at Hepion Pharmaceuticals, Inc. (HEPA), bought 1,250,000 shares at $0.04 ($50K) on 2026-04-21, disclosed to the SEC on 2026-04-27.
Director Michael J. Purcell executed the largest insider purchase in Hepion's history by buying 1.25 million shares at $0.04, signaling strong conviction in the biotech's future. This aggressive accumulation occurs as the stock sits near its 52-week high, potentially attracting momentum-focused traders.
The stock is currently trading at $0.3181, up 3% over the last 30 days and essentially flat against its 52-week high of $0.3181.
The stock faces significant liquidity risk with a market cap of only $1.75M and a short interest of 4.1% of the float, which could amplify volatility if sentiment shifts.
Nothing distinguishes this filing.
| Filing → |
| TRHC | BUY | 2022-03-03 | $58K | — | Filing → |
| IMXI | BUY | 2021-11-22 | $105K | — | Filing → |
| TRHC | BUY | 2021-11-12 | $273K | — | Filing → |